Home LiteratureArticle Details
PMID: 17031467 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells.

Archivum immunologiae et therapiae experimentalis ·Vol. 54 ·No. 5 ·2006-00-00 ·Pages 323-33

Poggi A, Zocchi MR

Abstract

Spontaneous tumors grow and kill the host unless therapy reduces their mass to a level where the immune system, it is thought, can control their growth and diffusion. Indeed, in many instances tumors can reappear, become resistant to therapy, and escape the host immune response. Many mechanisms of tumor escape operating in the tumor microenvironment have been proposed: 1) low or absent expression of molecules on tumor cells involved in tumor target cell recognition; 2) absence of co-stimulation leading to tolerization of T cells; 3) soluble factors secreted by tumor cells inhibiting T cell response; and 4) regulatory T cells, myeloid suppressor cells, and stromal cells may impair immune-cell responses to tumors. Furthermore, tumors can release soluble molecules such as HLA-I (sHLA-I). This, in turn, reduces T cell-mediated immune response and induces apoptosis of cytolytic effector cells such as natural killer and CD8(+) T lymphocytes through the engagement of HLA-I receptors such as CD8 and/or activating isoforms of the inhibitory receptor superfamily. The release of soluble ligand for activating receptors, e.g. UL16 binding proteins and/or MHC class I-related proteins A and B, the natural ligands of NKG2D, may impair activation, effector cell-mediated recognition, and cytolysis of tumor cells. Furthermore, the elimination of anti-tumor effector cells may be achieved by induction of apoptosis consequent to triggering elicited via activating molecules, such as receptors responsible for natural cytotoxicity, upon their binding with ligands expressed on tumor cells.

MeSH Terms
Animals Apoptosis/immunology CD8-Positive T-Lymphocytes/immunology Cyclosporine/immunology,therapeutic use Humans Interferon-gamma/immunology Killer Cells, Natural/immunology Macrophages/immunology Neoplasms/immunology T-Lymphocytes/immunology Transforming Growth Factor beta/metabolism Tumor Escape/immunology
Chemicals
Transforming Growth Factor beta Interferon-gamma Cyclosporine
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Poggi Alessandro
Laboratory of Experimental Oncology D, National Institute for Cancer Research, c/o CBA Torre A1, Largo R. Benzi 10, 16132 Genoa, Italy. alessandro.poggi@ostge.it
Zocchi Maria Raffaella
Article Info
Journal
Archivum immunologiae et therapiae experimentalis
Abbr.
Arch Immunol Ther Exp (Warsz)
ISSN
0004-069X
Published
2006-00-00
Epub
2006-00-06
Pages
323-33
Language
English
Region
Switzerland
NLM ID
0114365
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com